ePrints

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network

Lookup NU author(s): Professor Gareth VealORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).

Abstract

Copyright © 2026 The Authors. Ear & Hearing is published on behalf of the American Auditory Society, by Wolters Kluwer Health, Inc. Objectives: – Sodium thiosulfate (STS) has recently been approved as an otoprotectant for systemic use in pediatric cancer patients receiving cisplatin treatment for localized, nonmetastatic solid tumors by the Food and Drug Administration, European Medicines Agency, and Medicines and Healthcare Products Regulatory Agency. While incorporating STS into the current standard of care pediatric practice, questions about uniform, timely, and safe administration are raised that may benefit from additional guidance. Design: – Recognizing that advancing clinical practice presents multiple challenges, an international onco-ototoxicity prevention task force, including experts in pediatric oncology, audiology, and pharmacology, was established to identify potential barriers to the implementation of otoprotection and to offer practical solutions for clinical services for children exposed to cisplatin, based on available evidence, as well as consensus where data are less robust. This task force held several online meetings and a working group session at the annual SIOPE meeting in Milan in May 2024, where the challenges for implementing STS were outlined and addressed. Results: – Nine key challenges were identified, including, for example, the timing of both cisplatin infusion and STS administration, the optimal integration of STS into existing treatment protocols, potential drug interactions, and relevant economic considerations. Conclusion: – In this article, we propose practical steps to address these challenges, informed by the existing literature and expert opinion, incorporating recommendation statements from the international onco-ototoxicity prevention task force on behalf of the SIOP Supportive Care Network, to facilitate the implementation of STS in children with localized, nonmetastatic disease.

Publication metadata

Author(s): Streefkerk N, Geller JI, Knight K, Ansari M, Papadakis V, Calaminus G, Masroor A, Huitema ADR, Pasqualini C, Rutkowski S, Bouffet E, am Zehnhoff-Dinnesen A, Caniza M, van de Wetering MD, Delano P, Rajput KM, Weerdenburg H, Frazier AL, Hoetink AE, van Grotel M, Gaspar N, Shaikh F, Fresneau B, O'Neill AF, Veal GJ, Sullivan M, Brock PR, van den Heuvel-Eibrink MM

Publication type: Article

Publication status: Published

Journal: Ear and Hearing

Year: 2026

Pages: Epub ahead of print

Online publication date: 26/06/2026

Acceptance date: 02/04/2018

Date deposited: 01/09/2026

ISSN (print): 0196-0202

ISSN (electronic): 1538-4667

Publisher: Wolters Kluwer Health

URL: https://doi.org/10.1097/AUD.0000000000001856

DOI: 10.1097/AUD.0000000000001856

Altmetrics

Share